Indice 2021, 6

Antonio Iñesta. Blog Web2.0 y Salud http://fecoainesta.blogspot.com.es/

Esta es la sexta parte del Índice de los Blogs publicados en 2021. Debido a que este Indice no cabe en un solo Blog lo he dividido en varias entregas. Los grupos son:

*Medicamentos contra el Cáncer aprobados en 2021

*Indice principios activos, Clasificación y Nombre comercial de los MED contra el Cáncer aprobados en 2021

*Medicamentos contra el Cancer por Indicaciones, en 2021

*Medicamentos contra el Cancer por Grupos, comercializados hasta 2021

*Pruebas de diagnóstico acompañante de los MED contra el Cáncer aprobados en 2021

*Medicamentos contra el Cáncer que pronto estarán comercializados

*Medicamentos contra el Cáncer que pronto estarán comercializados 15-26

Cáncer, EEUU, España, Inmunoterapia, Medicamentos, Revisión acelerada oncológicos para registro, Salud, Unión Europea. Blogs: 25/01/2021, 3/02/2021, 16/03/2021, 16/04/2021, 5/05/2021, 3/06/2021, 5/07/2021, 3/08/2021, 3/09/2021, 5/10/2021, 10/11/2021, 5/12/2021.

Fas Fast Track designation (Vía rápida); Bre Breakthrough Therapy designation (Terapia innovadora); Pri Priority Review (Revisión prioritaria); NDA New Drug Application (Solicitud de nuevo medicamento)

-Abatacept (Orencia, Bristol-Myers Squibb; FDA, EMA, España DH y UH), Blog 3/09/2021; Adagrasib (Mirati Therapeutics), Blog 5/07/2021; AIC100 (AffyImmune Therapeutics), Blog 3/06/2021; ALLO-605 (Allogene Theraputics), Blogs: 5/05/2021, 3/09/2021; Alpha Diffusing Alpha-emitters Radiation Therapy (DaRT) (Alpha Tau Medical), Blog 10/11/2021; Alrizomadlin (Ascentage Pharma), Blog 5/10/2021; Amivantamab (Janssen), Blog 25/01/2021; Anamicina (Annamycin, Moleculin Biotech, Inc), Blog 16/04/2021; Arfolitixorina (Isofol Medical AB), Blog 5/12/2021; ARX788 (Ambrx, Inc.), Blog 3/02/2021; Asciminib (ABL001, Novartis), Blogs: 16/03/2021, 3/09/2021; Asparaginasa encapsulada en eritrocitos (Eryaspase, Erytech Pharma), Blog 3/08/2021; Atezolizumab (Tecentriq, Genentech; FDA, EMA, España UH), Blog 3/09/2021; Axicabtagén ciloleucel (Yescarta, Kite Pharma (una Gilead Company); FDA, EMA, España UH), Blog 10/11/2021;

-Balstilimab (Agenus Inc.), Blog 5/07/2021; BAT1706 (Bio-Thera Solutions), Blog 3/02/2021; Belzutifan (MK-6482, Merck), Blog 16/04/2021; Bemarituzumab (Amgen), Blog 5/05/2021; Bemcentinib (BGB324, BerGenBio ASA) en combinación con un anti PD-L1, Blogs: 5/07/2021, 5/12/2021; Betibeglogén autotemcel (Beti-cel, Bluebird bio, Inc.), Blogs: 5/10/2021, 5/12/2021; BNT111 (FixVac, BioTech SE), Blog 5/12/2021; Brexucabtagén autoleucel (Tecartus, Kite; FDA, EMA condicional), Blog 5/05/2021;

-Cabozantinib (Cabometyx, Exelixis; FDA, EMA, España DH), Blogs: 16/03/2021, 3/09/2021; Cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals; FDA, EMA, España UH autorizado no comercializado), Blog 5/10/2021; Copanlisib (Aliqopa, Bayer HealthCare; FDA, EMA huérfano), en combinación de rituximab (Rituxan, Genentech; FDA, EMA, España UH), Blog 5/07/2021; CT-0508 (Carisma Therapeutics, Inc.), Blog 5/10/2021; CTX110 (CRISPR Therapeutics), Blog 5/12/2021; CYNK-001 (Celularity), Blog 16/04/2021;

-DAY101 (Day One Biopharmaceuticals), Blog 3/08/2021; Devimistat (Rafael Pharmaceuticals), Blog 25/01/2021;

-Enfortumab vedotina-ejfv (Padcev, Astellas Pharma, Inc and Seagen, Inc), Blog 5/05/2021; EZM0414 (Epizyme, Inc), Blog 5/12/2021;

-Ftilagimod alfa A (Immutep Limited.), Blog 5/05/2021; Futibatinib (TAS-120, Taiho Oncology, Inc), Blog 5/05/2021; 

-GEN-1 (Celsion Corporation), Blog 16/03/2021;

-5hmC assay (Bluestar Genomics), Blog 5/05/2021;

-IN10018 (InxMed, Co. Ltd.), Blog 3/09/2021; Infigratinib (BridgeBio Pharma, Inc), Blog 25/01/2021; Irinotecan liposoma injection (Onivyde, Ipsen), Blog 25/01/2021; Ivosidenib tablets (Tibsovo, Servier Pharmaceuticals; FDA; EMA huerfano), Blogs: 16/04/2021, 3/06/2021;

-Leronlimab (CytoDyn, Inc), Blog 5/12/2021; Lorlatinib (Lorbrena, Pfizer), Blog 25/01/2021; Lutetium (Lu-177) omburtamab-DTPA (Y-mAbs Therapeutics, Inc.), Blog 10/11/2021; Lutetium (Lu-177) vipivotida tetraxetan (177Lu-PSMA-617, Advanced Accelerator Applications/Novartis), Blogs: 5/07/2021, 5/10/2021;

-MT-6402 (Molecular Templates, Inc), Blog 5/12/2021; 

-Narsoplimab (OMS721, Omeros Corporation), Blog 3/02/2021; Nemvaleukina alfa (ALKS 4230, Alkermes plc), Blog 10/11/2021, 3/09/2021; Nivolumab (Opdivo, Bristol-Myers Squibb; FDA, EMA, España UH), Blogs: 3/02/2021, 5/05/2021; Nivolumab (Opdivo, Bristol Myers Squibb) con quimioterapia conteniendo fluoropirimidina y platino, Blog 3/02/2021; Nivolumab en combinación con ipilimumab (Opdivo y Yervoy, Bristol-Myers Squibb; FDA, EMA, España UH) y fluoropirimidina y quimioterapia conteniendo platino, Blog 5/10/2021; NovoTTF-200T System (Novocure), Blog 5/10/2021; NUC-1031 (Acelarin, NuCana plc), Blog 5/10/2021;

-Olaparib (Lynparza, AstraZeneca Pharms; FDA; EMA; España DH), Blog 5/12/2021; Orelabrutinib (InnoCare Pharma), Blog 5/07/2021;

-Pacritinib (CTI BioPharma Corp.), Blogs: 5/05/2021, 5/07/2021, 5/12/2021; Pafolacianina sodica inyección (Target Laboratories), Blog 16/04/2021; Parsaclisib (Incyte Corporation), Blog 5/12/2021; Pembrolizumab (Keytruda, Merck Sharp & Dohme; FDA, EMA, España UH), Blog 3/09/2021; Pembrolizumab (Keytruda, Merck Sharp & Dohme; FDA, EMA, España UH) y lenvatinib (Lenvima, Eisai; FDA, EMA, España DH), Blog 3/06/2021; Pembrolizumab (Keytruda, Merck & Co.; FDA, EMA, España UH) en combinación con quimioterapia, Blog 25/01/2021; Penpulimab (AK105, Akeso), Blog 3/06/2021; Plinabulina (BeyondSpring, Inc.) en combinación con G-CSF, Blogs: 16/04/2021, 5/07/2021; Poziotinib (Spectrum Pharmaceutical), Blog 16/04/2021; ProSense (IceCure Medical Ltd), Blog 5/05/2021;

-RaDaR assay (Inivata), Blog 5/05/2021; Repotrectinib (TPX-0005, Turning Point Therapeutics), Blog 10/11/2021; Retifanlimab (Incyte), Blog 3/02/2021; Ropeginterferon alfa-2b-njft (PharmaEssentia USA Corporation), Blog 3/06/2021; Ruxolitinib (Jakafi/Incyte, Jakavi/ Novartis; FDA, EMA, España DH), Blog 16/03/2021;

-SH-111 (Shorla Pharma Limited), Blog 5/05/2021; Signatera (Natera, Inc.), Blog 5/05/2021; Silmitasertib (CX-4945, Senhwa Biosciences, Inc), Blog 3/09/2021; Sintilimab (Tyvyt, Innovent Biologics) en combinación con pemetrexed y quimioterapia con platino, Blog 3/06/2021; nab-Sirolimus ABI-009 (Fyarro, Aadi Bioscience), Blog 3/08/2021; SNDX-5613 (Syndax Pharmaceuticals, Inc.), Blog 5/07/2021; Sotorasib (Amgen), Blogs: 25/01/2021, 16/03/2021; STRO-002 (Sutro Biopharma, Inc), Blog 3/09/2021; Surufatinib (HMPL 012, Hutchmed Limited), Blogs: 3/06/2021, 3/08/2021;

-Tebentafusp (IMCgp100, Immunocore Holdings Plc), Blog 3/09/2021; TH1902 (Theratechnologies Inc), Blog 16/03/2021; Tiosulfato sódico formulación (Pedmark, Fennec Pharmaceuticals), Blog 5/07/2021; Tipifarnib (Zarnestra, Kura Oncology; EMA Huérfano), Blog 16/03/2021; Tiragolumab (Roche), Blog 3/02/2021; Tisagenlecleucel (Kymriah, Novartis; FDA, EMA, España UH), Blog 10/11/2021; Tislelizumab (Novartis), Blog 5/10/2021; Tisotumab vedotina (Seagen Inc and Genmab A/S), Blogs: 16/03/2021, 5/05/2021; Toripalimab (Shanghai Junshi Biosciences Co.); Toripalimab (Junshi Biosciences y Coherus), Blogs: 3/02/2021, 16/04/2021, 5/12/2021; Toripalimab (Shanghai Junshi Biosciences Co.) en combinación con gemcitabina y cisplatino, Blog 3/09/2021; Trastuzumab deruxtecan (Enhertu; Daiichi Sankyo; FDA, EMA, España UH autorizado no comercializado), Blog 10/11/2021; Trilaciclib (Cosela, G1 Therapeutics, Inc), Blog 3/08/2021; Trinetta (Datar Cancer Genetic, Inc.), Blog 5/12/2021

-Ublituximab (TGTX-1101, TG Therapeutics) en combinación con umbralisib (Ukoniq, TG Therapeutics), Blogs: 25/01/2021, 3/06/2021; UriFind test (AnchorDx.), Blog 3/08/2021;

-Venetoclax (Venclexta, AbbVie Inc. y Genentech Inc.; FDA, EMA, España DH) en combinación con azacitidina (Vidaza, Celgene Corporation; FDA, EMA, España UH), Blog 3/08/2021; Vicineum (Sesen Bio), Blog 16/03/2021; VS-6766 (Verastem) y defactinib (VS-6063, Verastem), Blog 3/06/2021;

-WP1066 (Moleculin Biotech, Inc.), Blog 5/05/2021;

-Zanubrutinib (Brukinsa, BeiGene, Ltd.; FDA, EMA Huérfano), Blogs: 16/03/2021, 3/06/2021; Zenocutuzumab (MCLA-128, Merus N.V.), Blog 3/02/2021.